AlloVir

AlloVir is a biotechnology startup founded in 2013 and headquartered in the United States. The company is a pioneer in the development of allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. AlloVir's technology platforms aim to provide commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. Their innovative technology and manufacturing process enable the potential treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. Furthermore, the company is actively advancing multiple mid- and late-stage clinical trials across its product portfolio. Their most recent investment of $75.00M in post-IPO equity was made on 21 June 2023.